With investors increasingly focusing on ESG topics, you might think that being a Tech for Good company would help attract funding. This is not always the case, says Marc Gitzinger, CEO of...
With investors increasingly focusing on ESG topics, you might think that being a Tech for Good company would help attract funding. This is not always the case, says Marc Gitzinger, CEO of Bioversys, which is developing new medicines for severe life-threatening bacterial infections that are resistant to antibiotics.
In episode five, Gitzinger says the biotech industry still focuses mainly on financial returns and calls on impact investors to pay more attention to the topic of equitable health to ensure access and proper control of good quality drugs throughout the world.
Gitzinger discusses how he defines success, including the importance of generating financial returns for the investors who have believed in the technology and backed the business.
Our book for May is a very important book that has received considerable attention and praise, all fully justified. It speaks to business, of course – work design, product design – but...
YouTube
March 23, 2021 in Videos • 3 min read
LEGO Brand Group Executive Chairman says its strong performance during global lockdown this year was built on a deep-rooted culture of resilience and agility....
YouTubeMarch 23, 2021 in Videos • 1 min read
In an interview with IMD President Jean-François Manzoni, the head of Belgian chemicals multinational Solvay talks about how coronavirus could galvanize a much-needed international response to global warming...
YouTubeExplore first person business intelligence from top minds curated for a global executive audience
Share